Mundipharma
Anina von Planta is an experienced quality management professional with a strong background in the pharmaceutical and biotech industries. Currently serving as Quality Manager for Continual Improvement at Belimed since February 2021, Anina has previously held positions at Vifor Pharma as a Quality Assurance Specialist and at Roche as a QA Manager and QA Associate. Anina’s expertise includes ensuring compliance with regulatory standards, managing global Quality Management documents, performing root cause analyses, conducting internal audits, and leading global corrective and preventive actions (CAPAs). Anina holds a Master of Science in Molecular Biology and a Bachelor of Science in Biology from the University of Basel.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.